Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects

Convergent Mechanisms Underlying Rapid Antidepressant Action

(2018) Panos Zanos et al.   CNS DRUGS

Global arginine bioavailability ratio is decreased in patients with major depressive disorder

(2018) Toni Ali-Sisto et al.   JOURNAL OF AFFECTIVE DISORDERS

Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy

(2018) A.P. Allen et al.   JOURNAL OF PSYCHIATRIC RESEARCH

The Role of Indoleamine 2,3-Dioxygenase in a Mouse Model of Neuroinflammation-Induced Depression

(2018) Nikoletta Dobos et al.   JOURNAL OF ALZHEIMERS DISEASE

The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls

(2017) F.J.H. Sorgdrager et al.   JOURNAL OF AFFECTIVE DISORDERS

Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb

(2017) Maged M. Harraz et al.   Neurotherapeutics

Decreased serum L-arginine and L-citrulline levels in major depression

(2017) S. Hess et al.   PSYCHOPHARMACOLOGY

Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health

(2017) Igor Cervenka et al.   SCIENCE

Plasma sphingolipids and depressive symptoms in coronary artery disease

(2017) Adam Dinoff et al.   Brain and Behavior

Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation

(2016) Francesco Saverio Bersani et al.   BRAIN BEHAVIOR AND IMMUNITY

Plasma Biomarkers of Poor Muscle Quality in Older Men and Women from the Baltimore Longitudinal Study of Aging

(2016) Ruin Moaddel et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders

(2016) G Sanacora et al.   NEUROPSYCHOPHARMACOLOGY

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

(2016) D M Rotroff et al.   Translational Psychiatry

Inflammation: Depression Fans the Flames and Feasts on the Heat

(2015) Janice K. Kiecolt-Glaser et al.   AMERICAN JOURNAL OF PSYCHIATRY

Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory

(2015) Jillian M. Heisler et al.   BRAIN BEHAVIOR AND IMMUNITY

Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies

(2015) Gislaine Z. Réus et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Nitric Oxide-Related Biological Pathways in Patients with Major Depression

(2015) Andreas Baranyi et al.   PLoS One

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review

(2015) Nicolas D. Iadarola et al.   Therapeutic Advances in Chronic Disease

Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression

(2014) Helena Domin et al.   BEHAVIOURAL BRAIN RESEARCH

Elevated Plasma Ceramides in Depression

(2014) Patricia Gracia-Garcia et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions

(2013) George Anderson et al.   CNS & Neurological Disorders-Drug Targets

Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments

(2013) Gregory Oxenkrug   CURRENT DRUG TARGETS

Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression

(2013) Andrew H Miller   NEUROPSYCHOPHARMACOLOGY

Characterization of Acid Sphingomyelinase Activity in Human Cerebrospinal Fluid

(2013) Christiane Mühle et al.   PLoS One

Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death

(2012) James R. Van Brocklyn et al.   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY

Mortality and Suicide Risk in Treatment-Resistant Depression: An Observational Study of the Long-Term Impact of Intervention

(2012) Bryan Olin et al.   PLoS One

Ketamine use: a review

(2011) Celia J. A. Morgan et al.   ADDICTION

Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography

(2011) Harald Sourij et al.   ATHEROSCLEROSIS

Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder

(2011) M. Elizabeth Sublette et al.   BRAIN BEHAVIOR AND IMMUNITY

Nitric oxide synthases: regulation and function

(2011) U. Forstermann et al.   EUROPEAN HEART JOURNAL

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

(2010) Nancy Diazgranados et al.   ARCHIVES OF GENERAL PSYCHIATRY

Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder

(2010) Nancy DiazGranados et al.   JOURNAL OF CLINICAL PSYCHIATRY

Metabolomic Differences in Heart Failure Patients With and Without Major Depression

(2010) David C. Steffens et al.   JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY

The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression

(2010) M. Maes et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Metabolomics-based methods for early disease diagnostics

(2008) GA Nagana Gowda et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS